ArticleMikrochimica acta2025
A 3D-printed handheld microfluidic device for sensitive and low-cost on-site immunodetection.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A portable, sensitive and low-cost immuno-detection microfluidic device for on-site application has been developed. The microfluidic device comprised a mask stereolithography (MSL)-based 3D-printed microfluidic chip and a handheld chemiluminescence reader. The MSL-fabricated microfluidic chip is characterized by its fast and economical prototype production process. Furthermore, the naturally generated micro-pits and micro-wavy structures during the printing process offered abundant surface area for antibody binding, which was beneficial for the assay sensitivity. The matched compact and lightweight chemiluminescence reader was designed for handheld use without compromising performance in signal intensity measurements, which were as sensitive as the commercial microplate reader. Employing this device, we developed a fast and simple detection workflow for the vital inflammation-related biomarker interleukin-6 (IL-6). Under suitable conditions, the device achieved a low limit of detection (LOD) of 0.5 pg/mL and a wide quantitative range from 0 to 800 pg/mL, covering the physiological levels of IL-6 in the human body. Moreover, validation studies involving 35 real samples and recovery analysis of IL-6-spiked serum samples confirmed the reliability and feasibility of the device for real-world applications. Capitalizing on its advantages, the microfluidic device demonstrates significant potential for on-site immunodetection applications in resource-limited settings.
Indexed as
Identifiers
41348327What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.